Amryt Pharma Holdings Ltd
LSE:AMYT
Amryt Pharma Holdings Ltd
LSE:AMYT
Price:
143
GBX
-11.73%
Market Cap:
£457.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amryt Pharma Holdings Ltd
Cash from Operating Activities
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Amryt Pharma Holdings Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
Cash from Operating Activities
$26.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£7.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
12%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$14.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
25%
|
CAGR 10-Years
16%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$436m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Operating Activities
-£32.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cash from Operating Activities
£38.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
No Stocks Found
Amryt Pharma Holdings Ltd
Glance View
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.
AMYT
Intrinsic Value
Not Available
See Also
What is Amryt Pharma Holdings Ltd's Cash from Operating Activities?
Cash from Operating Activities
26.9m
USD
26.9m
USD
Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Cash from Operating Activities amounts to 26.9m USD.
